HeartMate 3 LVAD

With Full Maglev Flow Technology

Advanced Heart Failure Patient Management

OVER 6.7 MILLION adults in the United States have heart failure.1

Heart failure is a complex, progressive disease that can be challenging to manage.2,3 It is associated with a markedly poor prognosis and significantly reduced quality of life, leading to increased risk of death.2,3

Help your advanced heart failure patients understand if HeartMate 3™ LVAD therapy might be a treatment option before their heart failure worsens.

The mortality rate for heart failure

INCREASED BY 24%4
(between 2011-2017)

Patients hospitalized for heart failure have a

MEDIAN SURVIVAL OF < 2.4 YEARS5

Heart failure in the United States is attributed to

1 in 8 Deaths Per Year4

Stay up-to-date on proven long term, life-extending therapy for advanced heart failure patients.

Sign Up
Patients can benefit from the HeartMate 3 LVAD
Patients can benefit from the HeartMate 3 LVAD

Advanced Heart Failure Therapy

Clinicians play a critical role in identifying heart failure progression early enough to help prevent heart failure-related hospitalizations, improve quality of life and extend survival for patients.

Even with optimal medical management, medications can become less effective as heart failure progresses. It’s important to recognize when medications alone are not enough, and when advanced therapies need to be considered for late stage heart failure patients.3

Fortunately, continuous innovation is creating more options for patients with advanced heart failure, offering more hope for a better quality of life.

Today, left ventricular assist
devices (LVADs) are making a better
future possible for many patients
with advanced heart failure.6

Manuals & Resources

Manuals & Resources

Find a HeartMate 3 LVAD Center

Find a HeartMate 3 LVAD Center

Customer Service

Customer Service

References

  1. Bozkurt, B, Ahmad, T, Alexander, KM, et al. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. Journal of Cardiac Failure DOI:https://doi.org/10.1016/j.cardfail. 2023.07.006.
  2. Rogers JG, Pagani F, Tatooles A, et al. Intrapericardial left ventricular assist device for advanced heart failure. New Engl J Med. 2017;376:451-460.
  3. AbouEzzeddine OF, Redfield MM. Who has advanced heart failure? Definition and epidemiology. Congest Heart Fail. 2011;17:1-18.
  4. Virani SS, Alonso A, Aparicio, HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143:e254–e743.DOI: 10.1161/CIR.0000000000000 950.
  5. Setoguchi S, Stevenon LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2009;154:260-266.
  6. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  7. Hscich, EM. Matching the Market for Heart Transplantation. Circ Heart Fail. 2016;9:e002679.

MAT-2012368 v4.0